Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives $32.00 Consensus PT from Analysts

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) has been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $32.00.

ODTX has been the topic of several recent analyst reports. TD Cowen began coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating for the company. JPMorgan Chase & Co. started coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “overweight” rating and a $26.00 target price for the company. Wedbush began coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, Wall Street Zen cut shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th.

Insider Activity

In other news, Director Nan (Ln) Li bought 1,111,111 shares of Odyssey Therapeutics stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the acquisition, the director owned 3,333,516 shares of the company’s stock, valued at $60,003,288. This trade represents a 50.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the transaction, the insider directly owned 1,831,383 shares of the company’s stock, valued at $32,964,894. This represents a 43.54% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 4,183,777 shares of company stock valued at $75,319,986.

Odyssey Therapeutics Stock Performance

NASDAQ:ODTX opened at $16.80 on Friday. Odyssey Therapeutics has a 12-month low of $15.35 and a 12-month high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last posted its quarterly earnings results on Wednesday, June 17th. The company reported ($6.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($5.46).